Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
NasdaqGS - Delayed Quote USD

Kyverna Therapeutics, Inc. (KYTX)

Compare
2.9000
+0.1200
+(4.32%)
At close: February 24 at 4:00:01 PM EST
2.8700
-0.03
(-1.03%)
After hours: 7:06:24 PM EST
Loading Chart for KYTX
DELL
  • Previous Close 2.7800
  • Open 2.8250
  • Bid 2.8800 x 100
  • Ask 2.9300 x 200
  • Day's Range 2.6767 - 2.9300
  • 52 Week Range 2.6450 - 30.6000
  • Volume 297,519
  • Avg. Volume 398,451
  • Market Cap (intraday) 125.198M
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -2.9600
  • Earnings Date Mar 24, 2025 - Mar 31, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 23.50

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

kyvernatx.com

119

Full Time Employees

December 31

Fiscal Year Ends

Recent News: KYTX

View More

Performance Overview: KYTX

Trailing total returns as of 2/24/2025, which may include dividends or other distributions. Benchmark is

.

YTD Return

KYTX
22.46%
S&P 500
1.73%

1-Year Return

KYTX
89.60%
S&P 500
17.58%

3-Year Return

KYTX
90.38%
S&P 500
39.51%

5-Year Return

KYTX
90.38%
S&P 500
85.48%

Compare To: KYTX

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: KYTX

View More

Valuation Measures

As of 2/24/2025
  • Market Cap

    125.41M

  • Enterprise Value

    -187.04M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    0.40

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -34.79%

  • Return on Equity (ttm)

    -59.58%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -110.66M

  • Diluted EPS (ttm)

    -2.9600

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    321.59M

  • Total Debt/Equity (mrq)

    3.02%

  • Levered Free Cash Flow (ttm)

    -56.08M

Research Analysis: KYTX

View More

People Also Watch